Immediate and Long-Term Outcome of Upper Extremity Balloon Angioplasty in Giant Cell Arteritis

Abstract

Purpose:

To review the immediate and long-term results of subclavian, axillary, and brachial artery balloon angioplasty (PTA) in giant cell arteritis (GCA).

Case Reports:

Four patients (3 men; mean age 65±8.9 years) with upper limb claudication due to GCA underwent PTA for 2 stenoses and 1 occlusion of the subclavian artery, 6 stenoses and 2 occlusions of the axillary artery, and 2 stenoses of the brachial artery. Patients received steroids prior to the intervention, and steroid treatment was continued for at least 2 years. All procedures were performed successfully with no residual stenosis. At follow-up after 2 years (n=2), 5 years (n = 1), and 10 years (n = 1), no significant recurrent stenoses were detected by duplex scanning.

Conclusions:

PTA is a safe and effective therapy for stenotic lesions and occlusions of the upper limb arteries due to GCA. The long-term results seem to benefit from postprocedural therapy with steroids and aspirin.

Keywords

vasculitis subclavian artery axillary artery upper limb claudication percutaneous transluminal angioplasty steroids

Get full access to this article

View all access options for this article.

References

Schillinger

Haumer

Schillinger

. Outcome of conservative versus interventional treatment of subclavian artery stenosis. J Endovasc Ther. 2002; 9: 139–146.

Motarjeme

Gordon

. Percutaneous transluminal angioplasty of the brachiocephalic vessels: Guidelines for therapy. Int Angiol. 1993; 12: 260–269.

Jeanneret

Mahler

. Images in vascular medicine. Giant cell arteritis of axillary artery. Vasc Med. 1996; 1: 293–294.

Dellaripa

Eisenhauer

. Bilateral percutaneous balloon angioplasty of the axillary arteries in a patient with giant cell arteritis and upper extremity ischemic symptoms not responsive to corticosteroids. J Rheumatol. 1998; 25: 1429–1433.

Weyand

Goronzy

. Arterial wall injury in giant cell arteritis. Arthritis Rheum. 1999; 42: 844–853.

Weyand

Goronzy

. Pathogenic principles in giant cell arteritis. Int J Cardiol. 2000; 75(Suppl 1): S9–S19.

Ninet

Bachet

Dumontet

. Subclavian and axillary involvement in temporal arteritis and polymyalgia rheumatica. Am J Med. 1990; 88: 13–20.

Wilke

. What is the appropriate initial dose of corticosteroids to treat giant cell arteritis? Cleve Clin J Med. 2000; 67: 546–548.

Lambert

Weber

Boland

. Large vessel vasculitis without temporal artery involvement: Isolated form of giant cell arteritis? Clin Rheumatol. 1996; 15: 174–180.

10.

Rischmueller

Davies

Smith

. Three year follow-up of a case of giant cell arteritis presenting with a chronic cough and upper limb ischaemic symptoms. Br J Rheumatol. 1996; 35: 800–802.

11.

Kaiser

Weyand

Bjornsson

. Platelet-derived growth factor, intimal hyperplasia, and ischemic complications in giant cell arteritis. Arthritis Rheum. 1998; 41: 623–633.

12.

Hunder

Bloch

Michel

. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum. 1990; 33: 1122–1128.

13.

Tyagi

Verma

Gambhir

. Early and long-term results of subclavian angioplasty in aortoarteritis (Takayasu disease): Comparison with atherosclerosis. Cardiovasc Intervent Radiol. 1998; 21: 219–224.

14.

Weyand

Fulbright

Hunder

. Treatment of giant cell arteritis: Interleukin-6 as a biologic marker of disease activity. Arthritis Rheum. 2000; 43: 1041–1048.

15.

Weyand

Kaiser

Yang

. Therapeutic effects of acetylsalicylic acid in giant cell arteritis. Arthritis Rheum. 2002; 46: 457–466.